TCMD Stock Overview
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Tactile Systems Technology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.65 |
| 52 Week High | US$26.11 |
| 52 Week Low | US$9.70 |
| Beta | 1.21 |
| 1 Month Change | -10.89% |
| 3 Month Change | 2.23% |
| 1 Year Change | -16.81% |
| 3 Year Change | -75.48% |
| 5 Year Change | -70.56% |
| Change since IPO | 32.22% |
Recent News & Updates
Recent updates
Tactile Systems Technology, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 23
Does Tactile Systems Technology (NASDAQ:TCMD) Have A Healthy Balance Sheet?
Oct 10Capital Allocation Trends At Tactile Systems Technology (NASDAQ:TCMD) Aren't Ideal
Sep 16Is It Time To Consider Buying Tactile Systems Technology, Inc. (NASDAQ:TCMD)?
Jul 13Are Investors Undervaluing Tactile Systems Technology, Inc. (NASDAQ:TCMD) By 26%?
May 10Is Tactile Systems Technology (NASDAQ:TCMD) Using Too Much Debt?
Feb 16Is Tactile Systems Technology (NASDAQ:TCMD) A Risky Investment?
Oct 12Tactile Systems Technology GAAP EPS of -$0.23 misses by $0.09, revenue of $59.6M beats by $2.72M
Aug 01Is Tactile Systems Technology (NASDAQ:TCMD) A Risky Investment?
Jun 14Investors Could Be Concerned With Tactile Systems Technology's (NASDAQ:TCMD) Returns On Capital
Jan 20Some Investors May Be Worried About Tactile Systems Technology's (NASDAQ:TCMD) Returns On Capital
May 20Tactile Systems Technology EPS beats by $0.03, beats on revenue
May 03Have Tactile Systems Technology, Inc. (NASDAQ:TCMD) Insiders Been Selling Their Stock?
Mar 04Is Tactile Systems Technology (NASDAQ:TCMD) Likely To Turn Things Around?
Feb 19Can You Imagine How Tactile Systems Technology's (NASDAQ:TCMD) Shareholders Feel About The 44% Share Price Increase?
Dec 28
Shareholder Returns
| TCMD | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.9% | -2.9% | -3.2% |
| 1Y | -16.8% | -3.7% | 19.3% |
Return vs Industry: TCMD underperformed the US Medical Equipment industry which returned -3.7% over the past year.
Return vs Market: TCMD underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| TCMD volatility | |
|---|---|
| TCMD Average Weekly Movement | 6.6% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TCMD has not had significant price volatility in the past 3 months.
Volatility Over Time: TCMD's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 992 | Dan Reuvers | tactilemedical.com |
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company also provides Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders.
Tactile Systems Technology, Inc. Fundamentals Summary
| TCMD fundamental statistics | |
|---|---|
| Market cap | US$348.08m |
| Earnings (TTM) | US$28.52m |
| Revenue (TTM) | US$274.42m |
12.2x
P/E Ratio1.3x
P/S RatioIs TCMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TCMD income statement (TTM) | |
|---|---|
| Revenue | US$274.42m |
| Cost of Revenue | US$79.29m |
| Gross Profit | US$195.13m |
| Other Expenses | US$166.62m |
| Earnings | US$28.52m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 06, 2024
| Earnings per share (EPS) | 1.20 |
| Gross Margin | 71.11% |
| Net Profit Margin | 10.39% |
| Debt/Equity Ratio | 15.0% |
How did TCMD perform over the long term?
See historical performance and comparison